Maxwell Benjamin Sauder (Maxwell Sauder)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Atopic Dermatitis

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Journal of cutaneous medicine and surgery

This page only lists publications with an associated author ORCID identifier.

Publications

Cynthia Fournier, Maxwell Benjamin Sauder
Reader Comment Regarding "Survey of Oncologists and Dermatologists in Canada on the Management of Acneiform Eruptions Induced by Epidermal Growth Factor Receptor Inhibitors". Journal of cutaneous medicine and surgery (2023)
Wei Jing Loo, Irina Turchin, Vimal H Prajapati, Melinda J Gooderham, Parbeer Grewal, Chih-Ho Hong, Maxwell Benjamin Sauder, Ronald B Vender, Catherine Maari, Kim A Papp
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. Journal of cutaneous medicine and surgery 27 (1_suppl) (2022)
Wei Jing Loo, Irina Turchin, Vimal H Prajapati, Melinda J Gooderham, Parbeer Grewal, Chih-Ho Hong, Maxwell Benjamin Sauder, Ronald B Vender, Catherine Maari, Kim A Papp
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. Journal of cutaneous medicine and surgery 27 (1_suppl) (2022)
Wei Jing Loo, Irina Turchin, Vimal H Prajapati, Melinda J Gooderham, Parbeer Grewal, Chih-Ho Hong, Maxwell Benjamin Sauder, Ronald B Vender, Catherine Maari, Kim A Papp
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. Journal of cutaneous medicine and surgery 27 (1_suppl) (2022)
Wei Jing Loo, Irina Turchin, Vimal H Prajapati, Melinda J Gooderham, Parbeer Grewal, Chih-Ho Hong, Maxwell Benjamin Sauder, Ronald B Vender, Catherine Maari, Kim A Papp
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. Journal of cutaneous medicine and surgery (2022)
Maxwell Benjamin Sauder, Marcus Butler
Reader Comment Regarding "Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management". Journal of cutaneous medicine and surgery (2021)